Sanofi SA vs Zimmer Biomet Holdings Inc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Sanofi SA is far larger — about 6× Zimmer Biomet Holdings Inc's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SNY | ZBH | |
|---|---|---|
Market Cap | $104.83B | $17.36B |
Sector | Health | Health |
52-Week High | $52.34 | $107.71 |
52-Week Low | $41.33 | $79.58 |
Enterprise Value | $121.32B | $24.40B |
Dividend Yield | 5.5% | 1.07% |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →